General partner and founder of Columbus Venture Partners, Javier García spent  25 years at Eli Lilly and Company. He had senior management roles in Information Technology and Business Development. Led Lilly in several strategic investments as well as to the first closing of the 140 million fund with TVM where Lilly was a strategic limited partner.

Javier currently serves on the Board of several Biotech companies: Asklepios Biopharmaceutical (Based in North Carolina, US), Artax Biopharma (based in Boston,MA), Highlight Therapeutics (based in Valencia, Spain), Aura Biosciencies, Vivet Therapeutics and Viralgen Vector Core (based in San Sebastian, Spain). He also serves on the board since 2006 of the National Alliance for Hispanic Health and the Healthy Americas Foundation both in Washington DC.

Columbus INNVIERTE Life Sciences has already done several investments, some of them led by Columbus with flagship venture capital firms as coinvestors and partners like Novartis Venture Capital, Roche Ventures, HealthCap, Advent Life Sciences, Pappas Ventures, Henri Termeer, Ysios, Lundbeck Ventures, Arix Capital and Fresenius.
He participates with policy makers working on the future of the Biotech Sector in Spain and what legislation is needed to make the sector competitive in a global basis.

Mr. García received a Bachelor in Mathematics (Statistics and Operations Research) from Universidad Complutense of Madrid and a MBA from ICADE (Spain). He is fluent in English and Spanish and lived for more than 15 years in the US.